Pancreatic cancer drug trial halted after just two patients

NCT ID NCT05442749

Terminated Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial aimed to see if the drug niraparib could shrink tumors in people with metastatic pancreatic cancer that has certain gene mutations. Only 2 patients were enrolled before the study was terminated early, so we don't have enough information to know if it works. The drug was taken daily as a pill.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: niraparib
What this could lead to: If it had worked, niraparib could have offered a new targeted treatment option for a small group of pancreatic cancer patients with specific genetic mutations.
What could go wrong: The trial was terminated early with only 2 participants, so no meaningful conclusions can be drawn. Niraparib may not be effective for this cancer type, and side effects like liver issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC CANCER

Contacts and locations

Locations

Centre Georges François Leclerc

Dijon, 21079, France
Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France
Centre Hospitalier Universitaire Grenoble Alpes

Grenoble, 38043, France
Centre Léon Bérard

Lyon, 69373, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.